

Chapter 161

Sjögren's Syndrome

Gabor Illei & Stamatina Danielides

REFERENCES

1. Alamanos Y et al: Epidemiology of primary Sjogren's syndrome in north-west Greece, 1982–2003. *Rheumatology (Oxford)* **45**(2):187-191, 2006, [Epub 2005]
2. Foster H et al: Association of DR3 with susceptibility to and severity of primary Sjogren's syndrome in a family study. *Br J Rheumatol* **31**(5):309-314, 1992
3. Arnett FC et al: Genetic studies of Ro (SS-A) and La (SS-B) autoantibodies in families with systemic lupus erythematosus and primary Sjogren's syndrome. *Arthritis Rheum* **32**(4):413-419, 1989
4. Cobb BL et al: Genes and Sjogren's syndrome. *Rheum Dis Clin North Am* **34**(4):847-868, vii, 2008
5. Korman BD et al: Variant form of STAT4 is associated with primary Sjogren's syndrome. *Genes Immun* **9**(3):267-270, 2008
6. Miceli-Richard C et al: Association of an IRF5 gene functional polymorphism with Sjogren's syndrome. *Arthritis Rheum* **56**(12):3989-3994, 2007
7. Nordmark G et al: Additive effects of the major risk alleles of IRF5 and STAT4 in primary Sjogren's syndrome. *Genes Immun* **10**(1):68-76, 2009
8. Porola P et al: Androgen deficiency and defective intracrine processing of dehydroepiandrosterone in salivary glands in Sjogren's syndrome. *J Rheumatol* **35**(11):2229-2235, 2008
9. Spaan M et al: Healthy human salivary glands contain a DHEA-S processing intracrine machinery, which is deranged in primary Sjogren's syndrome. *J Cell Mol Med* 2010.
10. Gan YJ et al: Human oropharyngeal lesions with a defective Epstein-Barr virus that disrupts viral latency. *J Infect Dis* **168**(6):1349-1355, 1993
11. Sumida T et al: Expression of sequences homologous to HTLV-I tax gene in the labial salivary glands of Japanese patients with Sjogren's syndrome. *Arthritis Rheum* **37**(4):545-550, 1994
12. Triantafyllopoulou A, Tapinos N, Moutsopoulos HM: Evidence for coxsackievirus infection in primary Sjogren's syndrome. *Arthritis Rheum* **50**(9):2897-2902, 2004
13. Fox RI: Sjogren's syndrome. *Lancet* **366**(9482):321-331, 2005
14. Jonsson R et al: Expression of HLA-D-locus (DP, DQ, DR)-coded antigens, beta 2-microglobulin, and the interleukin 2 receptor in Sjogren's syndrome. *Clin Immunol Immunopathol* **45**(2):235-243, 1987
15. Kapsogeorgou EK, Moutsopoulos HM, Manoussakis MN: Functional expression of a costimulatory B7.2 (CD86) protein on human salivary gland epithelial cells that interacts with the CD28 receptor, but has reduced binding to CTLA4. *J Immunol* **166**(5):3107-3113, 2001
16. Tsunawaki S et al: Possible function of salivary gland epithelial cells as nonprofessional antigen-presenting cells in the development of Sjogren's syndrome. *J Rheumatol* **29**(9):1884-1896, 2002
17. Roescher N, Tak PP, Illei GG: Cytokines in Sjogren's syndrome. *Oral Dis* **15**(8):519-526, 2009
18. Bolstad AI et al: Increased salivary gland tissue expression of Fas, Fas ligand, cytotoxic T lymphocyte-associated antigen 4, and programmed cell death 1 in primary Sjogren's syndrome. *Arthritis Rheum* **48**(1):174-185, 2003
19. Emamian ES, et al: Peripheral blood gene expression profiling in Sjogren's syndrome. *Genes Immun* 2009
20. Gottenberg JE et al: Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. *Proc Natl Acad Sci USA* **103**(8):2770-2775, 2006
21. Hjelmervik TO et al: Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. *Arthritis Rheum* **52**(5):1534-1544, 2005
22. Daridon C et al: Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjogren's syndrome. *Arthritis Rheum* **56**(4):1134-1144, 2007
23. Lavie F et al: B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjogren's syndrome. *Scand J Immunol* **67**(2):185-192, 2008

24. Ittah M et al: Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR- and type-I IFN-dependent and -independent pathways. *Eur J Immunol* **38**(4):1058-1064, 2008
25. Mavragani CP, Tzioufas AG, Moutsopoulos HM. Sjogren's syndrome: autoantibodies to cellular antigens. Clinical and molecular aspects. *Int Arch Allergy Immunol* **123**(1):46-57, 2000
26. Robinson CP et al: Transfer of human serum IgG to nonobese diabetic Igmu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjogren's syndrome. *Proc Natl Acad Sci USA* **95**(13):7538-7543, 1998
27. Dawson L et al: Antimuscarinic antibodies in Sjogren's syndrome: where are we, and where are we going? *Arthritis Rheum* **52**(10):2984-2995, 2005
28. Roescher N et al: Peptide-based ELISAs are not sensitive and specific enough to detect muscarinic receptor type 3 autoantibodies in serum from patients with Sjogren's syndrome. *Ann Rheum Dis* **70**(1):235-236, 2011; [Epub 2010]
29. Bernacchi E et al: Xerosis in primary Sjogren syndrome: Immunohistochemical and functional investigations. *J Dermatol Sci* **39**(1):53-55, 2005
30. Roguedas AM et al: Cutaneous manifestations of primary Sjogren's syndrome are underestimated. *Clin Exp Rheumatol* **22**(5):632-636, 2004
31. Garcia-Carrasco M et al: Raynaud's phenomenon in primary Sjogren's syndrome. Prevalence and clinical characteristics in a series of 320 patients. *J Rheumatol* **29**(4):726-730, 2002
32. Fox RI, Liu AY: Sjogren's syndrome in dermatology. *Clin Dermatol* **24**(5):393-413, 2006
33. Mellgren SI, Goransson LG, Omdal R: Primary Sjogren's syndrome associated neuropathy. *Can J Neurol Sci* **34**(3):280-287, 2007
34. Mori K et al: The wide spectrum of clinical manifestations in Sjogren's syndrome-associated neuropathy. *Brain* **128**(Pt 11):2518-1234, 2005
35. Kassan SS, Moutsopoulos HM: Clinical manifestations and early diagnosis of Sjogren syndrome. *Arch Intern Med* **164**(12):1275-1284, 2004
36. Baimpa E et al: Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: clinical and pathophysiologic aspects. *Medicine (Baltimore)* **88**(5):284-293, 2009
37. Ioannidis JP, Vassiliou VA, Moutsopoulos HM: Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. *Arthritis Rheum* **46**(3):741-747, 2002
38. Vitali C et al: Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. *Ann Rheum Dis* **61**(6):554-558, 2002
39. Roescher N, Illei GG. Can quantified salivary gland scintigraphy results aid diagnosis of patients with sicca symptoms? *Nat Clin Pract Rheumatol* **4**(4):178-179, 2008
40. Mavragani CP, Moutsopoulos NM, Moutsopoulos HM. The management of Sjogren's syndrome. *Nat Clin Pract Rheumatol* **2**(5):252-261, 2006
41. Vivino FB et al: Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. *Arch Intern Med* **159**(2):174-181, 1999
42. Petrone D et al: A double-blind, randomized, placebo-controlled study of cevimeline in Sjogren's syndrome patients with xerostomia and keratoconjunctivitis sicca. *Arthritis Rheum* **46**(3):748-754, 2002
43. Sall K et al: Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. *Ophthalmology* **107**(4):631-639, 2000
44. Mavragani CP, Moutsopoulos HM. Conventional therapy of Sjogren's syndrome. *Clin Rev Allergy Immunol* **32**(3):284-291, 2007
45. Fox RI et al: Treatment of primary Sjogren's syndrome with hydroxychloroquine. *Am J Med* **85**(4A):62-67, 1988
46. Tishler M et al: Hydroxychloroquine treatment for primary Sjogren's syndrome: Its effect on salivary and serum inflammatory markers. *Ann Rheum Dis* **58**(4):253-256, 1999
47. Mariette X et al: Inefficacy of infliximab in primary Sjogren's syndrome: Results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). *Arthritis Rheum* **50**(4):1270-1276, 2004
48. Sankar V et al: Etanercept in Sjogren's syndrome: A twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. *Arthritis Rheum* **50**(7):2240-2245, 2004
49. Meijer JM et al: Effectiveness of rituximab treatment in primary Sjogren's syndrome: A randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* **62**(4):960-968, 2010

50. Pijpe J et al: Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjogren's syndrome. *Arthritis Rheum* **60**(11):3251-3256, 2009
51. Lodde BM et al: Experience with experimental biological treatment and local gene therapy in Sjogren's syndrome: Implications for exocrine pathogenesis and treatment. *Ann Rheum Dis* **65**(11):1406-1413, 2006

